LeMaitre Vascular (NASDAQ:LMAT) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research note issued on Wednesday, Zacks.com reports.
According to Zacks, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. "
Several other equities research analysts have also recently issued reports on the company. KeyCorp initiated coverage on LeMaitre Vascular in a report on Friday, February 12th. They issued a "sector weight" rating on the stock. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $55.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, April 30th. Roth Capital lifted their price target on shares of LeMaitre Vascular from $53.00 to $55.00 and gave the company a "neutral" rating in a research report on Tuesday. Finally, Barrington Research lifted their price objective on LeMaitre Vascular from $49.00 to $59.00 and gave the stock an "outperform" rating in a research report on Friday, April 30th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. LeMaitre Vascular has an average rating of "Hold" and a consensus target price of $49.67.
Shares of LeMaitre Vascular stock opened at $51.32 on Wednesday. The company has a fifty day moving average of $49.86 and a 200 day moving average of $43.52. LeMaitre Vascular has a fifty-two week low of $23.40 and a fifty-two week high of $54.96. The company has a market capitalization of $1.06 billion, a P/E ratio of 55.18, a P/E/G ratio of 3.52 and a beta of 1.43. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.27 and a current ratio of 2.30.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, April 29th. The medical instruments supplier reported $0.28 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.28. LeMaitre Vascular had a net margin of 15.41% and a return on equity of 12.32%. Analysts forecast that LeMaitre Vascular will post 1 EPS for the current year.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 48,150 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 3rd. The stock was sold at an average price of $51.20, for a total transaction of $2,465,280.00. Following the completion of the transaction, the chief executive officer now owns 2,796,567 shares in the company, valued at approximately $143,184,230.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 42,869 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $51.41, for a total transaction of $2,203,895.29. Following the transaction, the chief executive officer now directly owns 2,796,567 shares in the company, valued at approximately $143,771,509.47. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,816 shares of company stock worth $6,728,329. Company insiders own 16.50% of the company's stock.
Several large investors have recently bought and sold shares of LMAT. Sei Investments Co. raised its holdings in shares of LeMaitre Vascular by 10.4% in the 3rd quarter. Sei Investments Co. now owns 9,604 shares of the medical instruments supplier's stock worth $344,000 after purchasing an additional 905 shares during the period. Crossmark Global Holdings Inc. bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth approximately $239,000. Avantax Advisory Services Inc. bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth approximately $272,000. Nisa Investment Advisors LLC raised its holdings in LeMaitre Vascular by 2.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 10,280 shares of the medical instruments supplier's stock valued at $416,000 after acquiring an additional 280 shares during the period. Finally, Conestoga Capital Advisors LLC raised its holdings in LeMaitre Vascular by 0.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,893,192 shares of the medical instruments supplier's stock valued at $76,674,000 after acquiring an additional 9,153 shares during the period. 84.17% of the stock is currently owned by institutional investors.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.
Read More: What is a short straddle?
Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: How to Use the New Google Finance Tool7 Lithium Stocks That Will Power the Electric Vehicle Boom
Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.
But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.
And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.
The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.
View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom"